News & Updates
Filter by Specialty:
Vunakizumab safe, effective in moderate-to-severe plaque psoriasis
Treatment with vunakizumab, a novel interleukin 17A monoclonal antibody, shows promise for moderate-to-severe plaque psoriasis and good tolerability, according to the results of a recent study.
Vunakizumab safe, effective in moderate-to-severe plaque psoriasis
20 Jun 2022
RELIEVE-AD: Atopic dermatitis patients see rapid, sustained improvements with dupilumab
The biologic dupilumab appears to be a hit with atopic dermatitis (AD) patients treated in the real-world setting, with patients experiencing prompt improvements in multiple aspects of disease control that persisted through 1 year, as shown in the results of the RELIEVE-AD* study.
RELIEVE-AD: Atopic dermatitis patients see rapid, sustained improvements with dupilumab
17 Jun 2022
What is the most preferred first-line agent for paediatric alopecia areata?
In the treatment of paediatric alopecia areata (AA), an autoimmune, nonscarring hair loss disorder with a variable disease course and significant psychosocial impact, the most preferred first-line agent is topical corticosteroids, followed by contact immunotherapy, according to a study.